دورية أكاديمية
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
| العنوان: | Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. |
|---|---|
| المؤلفون: | Kakuru, Abel, Jagannathan, Prasanna, Muhindo, Mary K, Natureeba, Paul, Awori, Patricia, Nakalembe, Miriam, Opira, Bishop, Olwoch, Peter, Ategeka, John, Nayebare, Patience, Clark, Tamara D, Feeney, Margaret E, Charlebois, Edwin D, Rizzuto, Gabrielle, Muehlenbachs, Atis, Havlir, Diane V, Kamya, Moses R, Dorsey, Grant |
| بيانات النشر: | MASSACHUSETTS MEDICAL SOC |
| سنة النشر: | 2016 |
| المجموعة: | London School of Hygiene & Tropical Medicine: LSHTM Research Online |
| الوصف: | BACKGROUND: Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention of malaria in pregnant women in Africa. However, with the spread of resistance to sulfadoxine-pyrimethamine, new interventions are needed. METHODS: We conducted a double-blind, randomized, controlled trial involving 300 human immunodeficiency virus (HIV)-uninfected pregnant adolescents or women in Uganda, where sulfadoxine-pyrimethamine resistance is widespread. We randomly assigned participants to a sulfadoxine-pyrimethamine regimen (106 participants), a three-dose dihydroartemisinin-piperaquine regimen (94 participants), or a monthly dihydroartemisinin-piperaquine regimen (100 participants). The primary outcome was the prevalence of histopathologically confirmed placental malaria. RESULTS: The prevalence of histopathologically confirmed placental malaria was significantly higher in the sulfadoxine-pyrimethamine group (50.0%) than in the three-dose dihydroartemisinin-piperaquine group (34.1%, P=0.03) or the monthly dihydroartemisinin-piperaquine group (27.1%, P=0.001). The prevalence of a composite adverse birth outcome was lower in the monthly dihydroartemisinin-piperaquine group (9.2%) than in the sulfadoxine-pyrimethamine group (18.6%, P=0.05) or the three-dose dihydroartemisinin-piperaquine group (21.3%, P=0.02). During pregnancy, the incidence of symptomatic malaria was significantly higher in the sulfadoxine-pyrimethamine group (41 episodes over 43.0 person-years at risk) than in the three-dose dihydroartemisinin-piperaquine group (12 episodes over 38.2 person-years at risk, P=0.001) or the monthly dihydroartemisinin-piperaquine group (0 episodes over 42.3 person-years at risk, P<0.001), as was the prevalence of parasitemia (40.5% in the sulfadoxine-pyrimethamine group vs. 16.6% in the three-dose dihydroartemisinin-piperaquine group [P<0.001] and 5.2% in the monthly dihydroartemisinin-piperaquine group [P<0.001]). In each treatment group, the risk of vomiting after administration of any dose ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | text |
| اللغة: | English |
| العلاقة: | https://researchonline.lshtm.ac.uk/id/eprint/4652581/1/nejmoa1509150.pdfTest; Kakuru, Abel ; Jagannathan, Prasanna; Muhindo, Mary K; Natureeba, Paul; Awori, Patricia; Nakalembe, Miriam; Opira, Bishop; Olwoch, Peter; Ategeka, John; Nayebare, Patience; +8 more. Clark, Tamara D; Feeney, Margaret E; Charlebois, Edwin D; Rizzuto, Gabrielle; Muehlenbachs, Atis; Havlir, Diane V; Kamya, Moses R; Dorsey, Grant; (2016) Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. NEW ENGLAND JOURNAL OF MEDICINE, 374 (10). pp. 928-939. ISSN 0028-4793 DOI: https://doi.org/10.1056/NEJMoa1509150Test |
| الإتاحة: | https://doi.org/10.1056/NEJMoa1509150Test https://researchonline.lshtm.ac.uk/id/eprint/4652581Test/ https://researchonline.lshtm.ac.uk/id/eprint/4652581/1/nejmoa1509150.pdfTest |
| حقوق: | cr_publishers |
| رقم الانضمام: | edsbas.2011502A |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |